Immunotherapy with Pembrolizumab beyond Progression and Local Ablative Therapy in Oligoprogressive Metastatic Non-Small Cell Lung Cancer
- 1Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Basel, Basel, Switzerland
- 2Clinic of Radiotherapy and Radiation Oncology, Cantonal Hospital Baden, Baden, Switzerland
- 3Center of Oncology, Hematology and Comprehensive Cancer Center, Cantonal Hospital Baden, Baden, Switzerland
Abstract
Introduction: Immune checkpoint inhibitors (ICIs) targeting PD-(L)1 are standard first-line treatment for non-oncogene-addicted metastatic non-small cell lung cancer (mNSCLC). While disease progression typically requires therapy change, patients with oligoprogression (≤5 progressing sites) often continue ICI in combination with local ablative therapies. In this retrospective study, we aimed to evaluate the characteristics and outcomes of this treatment approach.
Methods: We retrospectively analyzed mNSCLC patients receiving first-line ICI-based therapy at University Hospital Basel (January 2016–March 2022). Patients with documented disease progression were categorized into treatment beyond progression (BPD), second-line treatment (2L), or best supportive care (BSC). We compared patient characteristics and overall survival (OS).
Results: Of 104 patients receiving first-line ICI treatment, 65 experienced disease progression: 21 (32%) received BPD, 30 (46%) received 2L, and 14 (22%) received BSC. Patient and disease characteristics were similar across groups, except for higher brain metastasis frequency in the BPD group (BPD: 67% vs. 2L: 20% vs. BSC: 29%; p = 0.002). After median follow-up of 17.9 months, time to first progression (5.4 vs. 5.3 months, p = 0.5) and median OS after progression (9.1 vs. 10.9 months, p = 0.35) were similar between BPD and 2L groups.
Conclusion: In this retrospective analysis, treatment BPD was not associated with an improved prognosis compared to 2L therapy. There is a need to improve and implement criteria to select patients who truly benefit from this treatment approach.
Related
- 1189 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors
- Local ablative treatment for oligoprogression during immunotherapy in metastatic non-small-cell lung cancer: a systematic review and meta-analysis
- Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial
- Isolated Adrenocorticotropic Hormone Deficiency Secondary to Pembrolizumab-Induced Hypophysitis: A Case of Life-Threatening Adrenal Crisis in a Patient With Metastatic Melanoma
- Pembrolizumab Activity in Tyrosine Kinase Inhibitor–Refractory Metastatic GIST: A Case Report
BibTeX
@article{oseledchyk2026immunotherapy,
title = {{Immunotherapy with Pembrolizumab beyond Progression and Local Ablative Therapy in Oligoprogressive Metastatic Non-Small Cell Lung Cancer}},
author = {Anton Oseledchyk and Leopold Häcker and Andreas Michael Schmitt and Till Wallrabenstein and Tobias Finazzi and David König and Sacha I. Rothschild},
journal = {Oncology Research and Treatment},
year = {2026},
month = sep,
doi = {10.1159/ort/aecag008},
url = {https://doi.org/10.1159/ort/aecag008},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Immunotherapy with Pembrolizumab beyond Progression and Local Ablative Therapy in Oligoprogressive Metastatic Non-Small Cell Lung Cancer
AU - Anton Oseledchyk
AU - Leopold Häcker
AU - Andreas Michael Schmitt
AU - Till Wallrabenstein
AU - Tobias Finazzi
AU - David König
AU - Sacha I. Rothschild
PY - 2026
DA - 2026/09/18
JO - Oncology Research and Treatment
DO - 10.1159/ort/aecag008
UR - https://doi.org/10.1159/ort/aecag008
AB - Introduction: Immune checkpoint inhibitors (ICIs) targeting PD-(L)1 are standard first-line treatment for non-oncogene-addicted metastatic non-small cell lung cancer (mNSCLC). While disease progression typically requires therapy change, patients with oligoprogression (≤5 progressing sites) often continue ICI in combination with local ablative therapies. In this retrospective study, we aimed to evaluate the characteristics and outcomes of this treatment approach. Methods: We retrospectively analyzed mNSCLC patients receiving first-line ICI-based therapy at University Hospital Basel (January 2016–March 2022). Patients with documented disease progression were categorized into treatment beyond progression (BPD), second-line treatment (2L), or best supportive care (BSC). We compared patient characteristics and overall survival (OS). Results: Of 104 patients receiving first-line ICI treatment, 65 experienced disease progression: 21 (32%) received BPD, 30 (46%) received 2L, and 14 (22%) received BSC. Patient and disease characteristics were similar across groups, except for higher brain metastasis frequency in the BPD group (BPD: 67% vs. 2L: 20% vs. BSC: 29%; p = 0.002). After median follow-up of 17.9 months, time to first progression (5.4 vs. 5.3 months, p = 0.5) and median OS after progression (9.1 vs. 10.9 months, p = 0.35) were similar between BPD and 2L groups. Conclusion: In this retrospective analysis, treatment BPD was not associated with an improved prognosis compared to 2L therapy. There is a need to improve and implement criteria to select patients who truly benefit from this treatment approach.
SN - 2296-5270
SN - 2296-5262
ER -